09Jul 2024
Long-term Results of mFOLFIRINOX vs Preoperative Chemoradiotherapy in Rectal Cancer

Long-term Results of mFOLFIRINOX vs Preoperative Chemoradiotherapy in Rectal Cancer

The study assessed the long-term outcomes of neoadjuvant chemotherapy with mFOLFIRINOX followed by chemoradiotherapy, surgery, and adjuvant chemotherapy versus the standard care of chemoradiotherapy, surgery, and adjuvant chemotherapy for locally advanced rectal cancer. In this study involving 820 patients, those receiving neoadjuvant mFOLFIRINOX showed improved 7-year disease-free survival (67.6% vs. 62.5%), metastasis-free survival (79.2% vs. 72.3%), and overall survival (81.9% vs. 76.1%) compared to standard care. These findings highlight neoadjuvant mFOLFIRINOX as a superior treatment option for enhancing long-term outcomes in this patient population.

  • #oncology

Like

Save

Share